Form 4: Seres Therapeutics Executive David S. Ege Reports Stock Transactions
SEC Form 4 Filing
David S. Ege, Executive Vice President and Chief Technology Officer of Seres Therapeutics, reports the acquisition and disposition of common stock related to restricted stock units.
Summary
- On May 15, 2024, David S. Ege, an executive at Seres Therapeutics, acquired 2,968 shares of common stock through the vesting of restricted stock units.
- On the same day, Ege sold 1,090 shares of common stock at an average price of $0.94 per share.
- These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 2, 2023, to cover taxes associated with the vesting of the restricted stock units.
- Following these transactions, Ege directly owns 75,734 shares of Seres Therapeutics common stock and 32,657 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions, with no inherent positive or negative sentiment. It reflects routine executive compensation and tax planning.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, which is common in the biopharmaceutical industry. It provides transparency into the executive's holdings and trading activities.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they are part of a pre-arranged plan and involve a relatively small number of shares.
Key Dates
| Date | Description |
|---|---|
| 2023-03-02 | Date of adoption of Rule 10b5-1 trading plan |
| 2024-02-15 | 25% of the restricted stock units vested and settled |
| 2024-05-15 | Date of stock acquisition and disposition |
| 2024-05-17 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.